KinasePro

Kinase Chemistry – Just a year and a half behind the times.

Archive for the ‘Lilly’ Category

Enzastaurin

Posted by kinasepro on June 19, 2007

aka LY-317615 is a Lilly ‘PKC’ inhibitor

O=C(C(C1=CN(C)C2=C1C=CC=C2)=C3C4=CN(C5CCN(CC6=NC=CC=C6)CC5)C7=C4C=CC=C7)NC3=O

WO/1995/17182
BMCL ‘03; Cancer Res. ‘05; Clinic

Posted in Lilly, PKC, Phase III | Leave a Comment »

Arxxant

Posted by kinasepro on June 19, 2007

aka Ruboxistaurin / LY333531 is a Lilly PKC-b inhibitor

O=C(N1)C(C2=CN(CCO[C@]([H])(CN(C)C)CC3)C4=CC=CC=C42)=C(C5=CN3C6=C5C=CC=C6)C1=O

J Med Chem ‘96; Org Lett ‘01; Science ‘96; clinic

Posted in Lilly, PKC, Phase III | Leave a Comment »

LY333531 / Arxxant

Posted by kinasepro on November 13, 2006

Hi Lilly, So are you guys any closer to market with this protein kinase C-beta inhibiting staurosporine analog, Ruboxistaurin, or not?

O=C(N1)C(C2=CN(CCO[C@]([H])(CN(C)C)CC3)C4=CC=CC=C42)=C(C5=CN3C6=C5C=CC=C6)C1=O

 

I see you announced today the ‘results‘ of your diabetic retinopathy phase iii study. The FDA asked for more data back in August, and its still not clear if we’re going to see an approval, a new trial, or a withdrawal.

J Med Chem 1996, 2664
Org lett 2001, 3409

Posted in Lilly, clinical | 4 Comments »